In this double-blind study, the efficacy and tolerability of a single dose of almotriptan (6.25 or
12.5 mg) was compared with placebo in the treatment of three consecutive migraine attacks …

A meta-analysis of pooled individual patient data from four randomized, placebo-controlled,
double-blind trials comparing several doses of almotriptan (n= 1908) with placebo (n= 386) …

Objective.—To determine whether treatment of migraine with almotriptan, when pain
intensity is mild, improves 1‐and 2‐hour pain‐free and sustained pain‐free rates compared …

Objective.—Evaluate the long‐term tolerability of almotriptan 12.5 mg for the treatment of
acute migraine attacks occurring over a 6‐month period. Background.—Almotriptan is a …

Background.—Results from open‐label trials with almotriptan and sumatriptan have shown
higher response rates when treatment was initiated early after acute migraine onset …

Objective.—Evaluate the effect of almotriptan on sustained pain‐free outcome in patients
with acute migraine. Methods.—Three randomized, double‐blind, placebo‐controlled trials …

Almotriptan is a novel and specific serotonin 5-HT1B/1D agonist for the acute treatment of
migraine. This randomized, single-dose, double-blind, multicentre, study assessed the …

Objective.—To evaluate the comparative efficacy and safety of oral almotriptan in treating
acute migraine attacks. Background.—Almotriptan is an oral selective sertonin1B/1D …

Almotriptan, the new selective 5‐HT1B/1D agonist, has a higher oral bioavailability than any
other triptan, with more than two thirds of the administered dose absorbed within the first …

Objective.—To evaluate prospectively the efficacy and safety of almotriptan 12.5 mg as
compared to placebo when administered within 1 hour of headache pain onset for the acute …